{"analyses":[{"ciLowerLimit":"0.959","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.450","estimateComment":"Hazard ratio is based on an unadjusted Cox's proportional hazard regression model stratified by induction regimen, pre-induction ISS, and response after transplantation, comparing the hazard rate of Ixazomib arm over the hazard rate of Placebo arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.179"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.82","upperLimit":"16.53","value":"12.3"},{"groupId":"OG001","lowerLimit":"7.49","upperLimit":"12.06","value":"9.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"278"}],"units":"Participants"}],"description":"Duration of the next line of therapy was defined as the time from the date of the first dose of the next line of therapy to the date of the last dose of the next antineoplastic therapy following study treatment or death due to any cause, whichever occurred first. Duration of the next line of therapy was analyzed on those participants who received the next line of therapy following the study treatment and duration was summarized using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alternate reasons.","id":"OG000","title":"Placebo"},{"description":"Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons. Participants who had any dose reductions due to AEs were not dose escalated.","id":"OG001","title":"Ixazomib Citrate"}],"paramType":"MEDIAN","populationDescription":"ITT Population was defined as all participants who were randomized and had post randomization data. Overall number of participants analyzed indicates the number of participants who started next line of therapy.","reportingStatus":"POSTED","timeFrame":"Up to 107 months","title":"Duration of the Next Line of Therapy","type":"SECONDARY","unitOfMeasure":"months"}